Corporate Action, English, IR, Listing Regulation, News, Other, Regulatory

Acarix changes Certified Adviser to Penser Bank AB

14 Sep

Acarix, a leader in acoustic and AI-based cardiac diagnostics, today announces a change of Certified Adviser.

Acarix AB has entered into an agreement with Erik Penser Bank regarding the position as Certified Adviser. Erik Penser Bank will take over as Certified Adviser on September 18, 2023. Until then, Redeye AB will continue to act as Certified Adviser to the company.

For more information contact:
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email helen.round@acarix.com 
Christian Lindholm, CFO, phone +46 705 118333, email christian.lindholm@acarix.com

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of coronary artery disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. The CADScor System has been used on more than 29,000 patients and is recommended as a first-line diagnostic aid as outlined in the clinical workflow developed in collaboration with the American College of Cardiology (ACC). Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix. For more information, please visit www.acarix.com. 

Attachments
Acarix changes Certified Adviser to Penser Bank AB

Acarix changes Certified Adviser to Penser Bank AB
Newer Acarix expands use of CADScor System into Osteopathic Medicine
Back to list
Older Kallelse till extra bolagsstämma i Acarix AB